GlobeNewswire

Grafana Labs Raises $220M to Accelerate Global Adoption and Development of Open Source Visualization and Observability Platform

Share

Company strengthens board of directors with enterprise software veterans, announces addition of tracing to its full Grafana Cloud observability platform.

NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Grafana Labs, the company behind the world’s most ubiquitous open and composable operational dashboards, today announced a $220 million Series C investment round, co-led by new investors Sequoia Capital and Coatue, with participation from existing investors Lightspeed Venture Partners, Lead Edge Capital, and GIC. The new investment values Grafana Labs at $3 billion (for crypto fans, that’s more than 60,500 BTC as of August 23 at 22:00 UTC), more than ten times the valuation of the Series A round just two years ago. As part of the funding, Carl Eschenbach, partner at Sequoia and former President and COO at VMware, and David Schneider, general partner at Coatue and former President at ServiceNow, will be joining the company’s board of directors.

The “actually useful” free forever tier of Grafana Cloud provides the industry’s most generous no-cost observability stack, and with the funding round, Grafana Labs is adding 50GB of traces to the 50GB of logs, 10,000 series of Prometheus metrics, and 3 Grafana dashboard users that come with the free offering. Both Grafana Cloud and the on-premises Grafana Enterprise Stack offering include access to free and commercial plugins, such as Elasticsearch, Jira, Datadog, Splunk, AppDynamics, Oracle, MongoDB, Snowflake, ServiceNow, and more.

“It’s been an incredible year at Grafana Labs, highlighted by the rapid adoption of Grafana Cloud, the growth of our Loki logs and Prometheus metrics offerings, the introduction of Tempo 1.0 for tracing, and the continued development of the Grafana frontend,” said Raj Dutt, co-founder and CEO at Grafana Labs. “This new investment of capital, as well as the addition of two highly experienced technology executives to our board, will focus us on accelerating product development to support our community’s and customers' success.”

“In just a few years, Grafana Labs has grown from a single open source project into a comprehensive platform that is widely used across the Fortune 500 and Forbes Global 2000, helping companies make better decisions based on actionable data,” said Eschenbach. “I see a lot of similarities between the growth at Grafana Labs and the early years at VMware: focusing on solving problems for developers, and scaling those solutions across the enterprise. We’re eager to partner with Grafana Labs and look forward to working with Raj and team to continue building world-class observability products.”

Grafana Labs has doubled its headcount since the beginning of the year, with nearly 500 Grafanistas working remotely in more than 40 different countries. As part of its mission to deliver value to enterprise customers, as well as to the open source community, Grafana Labs recently announced the acquisitions of k6 for modern load testing and Pace.dev for building developer tools.

“At ServiceNow, I was able to witness first-hand how difficult it is to build an effective observability system that can provide teams with a single view across the organization,” said Schneider. “We think that Grafana Labs and their vendor-neutral ‘big tent’ philosophy have made it easier for organizations to keep tabs on all of their systems from one single dashboard. We’re proud to support them in their mission to bring a revolutionary approach to the market.”

To learn more about Grafana Labs, and to try out Grafana Enterprise Stack and Grafana Cloud, visit https://grafana.com/.

About Grafana Labs

Grafana Labs provides an open and composable monitoring and observability stack built around Grafana, the leading open source technology for dashboards and visualization. There are over 1,500 Grafana Labs customers including Bloomberg, JP Morgan Chase, eBay, PayPal, and Sony, and more than 750,000 active installations of Grafana around the globe. Grafana Labs helps companies manage their observability strategies with full-stack offerings that can be run fully managed with Grafana Cloud, or self-managed with Grafana Enterprise Stack, both featuring extensive enterprise data source plugins, dashboard management, alerting, reporting and security, scalable metrics (Prometheus & Graphite), logs (Grafana Loki) and tracing (Grafana Tempo). Grafana Labs is backed by leading investors Lightspeed Venture Partners, Lead Edge Capital, GIC, Sequoia Capital, and Coatue. Follow Grafana on Twitter at @grafana or visit www.grafana.com.

Media Contact:
Dan Jensen, PR for Grafana Labs
dan.jensen@grafana.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)17.9.2021 13:30:00 CEST | Press release

PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced disease progression or death Alpelisib is the first potential treatment to specifically address the root cause of PROS conditions EPIK-P1 study findings presented at ESMO Virtual Congress 2021 support FDA submission Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and improved signs and symptoms in pediatric and adult patients. Resu

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS17.9.2021 13:15:00 CEST | Press release

Mechelen, Belgium;17September 2021;13.15 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced todaythatthe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issueda positive opinion for Jyseleca® (filgotinib), a once-daily, oral, JAK1preferential inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Following this positive opinion, a final decision from the European Commission is expected later this year. The CHMP positive opinion is based on data from the pivotal Phase 2b/3 SELECTION program, which evaluated filgotinib as an induction and maintenance therapy in adult patients with moderately to severely active UC who have failed conventional therapy or biologics. SELECTION comprised two placebo-controlled induction studies, one in biologic-naive patients and the o

Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer17.9.2021 13:10:00 CEST | Press release

Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusionsIf approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. “This positive CHMP opinion for Gavreto represents another important step towards our goal of providing effective therapeutics that target genomic drivers of disease for as many cancer patients as possible," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Developmen

Elina Stråhlman appointed as Enento Group’s acting CEO17.9.2021 13:00:00 CEST | Press release

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 17 SEPTEMBER 2021 AT 2.00 P.M. EEST Elina Stråhlman appointedas Enento Group’s acting CEO As communicated with a stock exchange release on 21 April 2021, Enento Group Plc’s current CEO Jukka Ruuska has given notice of his resignation from the company no later than 31 October 2021. As announced in July, Jeanette Jäger will start as the new CEO and member of the Executive Management Team on 1 January 2022. Since 2016 she has worked in the Swedish company Bankgirot, first as VP Digital Services and from 2017 as CEO of Bankgirot. Enento Group's Board of Directors has today appointed Elina Stråhlman, the Group’s CFO, as an acting CEO for the interim period from 1 November 2021 to 31 December 2021. ENENTO GROUP PLC For further information: Jukka Ruuska CEO Tel. +358 10 270 7111 Distribution: Nasdaq Helsinki Major media enento.com/investors Enento Group is a Nordic knowledge company powering society with intelligence since 1905. We collect and trans

Fobi Launches Connected Retail Commerce Solution At Industry’s Premier Event For Convenience, Grocers and CPG Brands17.9.2021 12:00:00 CEST | Press release

Fobi CEO Rob Anson and Senior Vice President of Business Development Mike Canevaro to launch new Personalized Digital Receipt Marketing Solution at GroceryShop to be held September 19-22 in Las Vegas, Nevada VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (TSX.V: FOBI) (OTCQB: FOBIF) (the "Company" or "Fobi"), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is excited to announce the launch of its latest solution. The Fobi connected retail commerce solution will support real-time POS data connectivity across all banners and channels, in-store, online and mobile to provide retailers and CPG manufacturers with the ability to deliver automated and personalized marketing at scale. PERSONALIZED MARKETING TO EMPOWER CPG BRANDS BY PROVIDING THEM WITH DIRECT ACCESS TO ENGAGE CONSUMERS WITH PROMOTIONS AND CAMPAIGN ACTIVATION MEASUREMENT Fobi will now enable manufacturer brands to gain

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 10:07:00 CEST | Press release

Auction date2021-09-17Loan1059Coupon1.00 %ISIN-codeSE0007125927Maturity2026-11-12Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,000Volume bought, SEK mln500Number of bids2Number of accepted bids1Average yield-0.028Lowest accepted yield-0.028Highest yield-0.028% accepted at lowest yield 100.00 Auction date2021-09-17Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 350Volume offered, SEK mln1,750Volume bought, SEK mln750Number of bids5Number of accepted bids1Average yield0.277Lowest accepted yield0.277Highest yield0.277% accepted at lowest yield 100.00

Riksgälden föreslår i stort oförändrade riktlinjer för statsskulden17.9.2021 09:30:00 CEST | Pressemelding

Riksgälden föreslår i stort oförändrade riktlinjer för statsskulden Riksgälden föreslår inga väsentliga ändringar i riktlinjerna för förvaltningen av statsskulden.Förslaget till riktlinjer för 2022lämnas till Finansdepartementet i dag. Riksgälden ser inte behov av några större ändringar i riktlinjerna efter att de justeringar som gjorts de senaste åren har lett till en mer övergripande styrning av skuldförvaltningen. Därmed har Riksgälden god flexibilitet att hantera stora variationer i statens lånebehov inom de ramar som riktlinjerna ger. Regeringen beslutar om riktlinjerna varje år senast den 15 november. Beslutet fattas efter att Riksgälden har lämnat sitt förslag och Riksbanken har yttrat sig över förslaget. I riktlinjerna fastställs bland annat hur statsskulden ska vara sammansatt och vilken löptid den ska ha. Riktvärden för sammansättning och löptid ligger fast Sammansättning Real kronskuld – andelen ska långsiktigt vara 20 procent av statsskulden.Skuld i utländsk valuta – expone